Peer-reviewed article
Regional inequality in infant RSV morbidity and mortality burden in the era of expanded RSV passive immunisation: a global projection modelling study
Shaolong Ren, Bingbing Cong, Jing Zou, Ling Guo, Harish Nair et al. ·
Summary
Written by AI, not yet AICS's view · claude-sonnet-5-5This modelling study estimates how much respiratory syncytial virus (RSV) disease in infants differs by world region and country income level, using 2019 data as a baseline. It then projects the effect of the new RSV products (nirsevimab and the maternal RSVpreF vaccine) as they were in use by June 2025. The products are mostly used in high-income countries, so the projected reduction in the global burden is small. The authors conclude that unequal access may widen existing inequality in RSV deaths and call for faster introduction in low- and middle-income countries.
Key points
- In 2019 the African Region had the highest RSV-associated lower respiratory infection incidence (117.4 per 1000 person-years) and the highest RSV-attributable mortality rate (0.97 per 1000 person-years), but the lowest hospital admission rate (12.6 per 1000 person-years).
- As of June 2025, nirsevimab was licensed in 54 countries and maternal RSVpreF in 64. Of these, 16 and 12 countries respectively had introduced them into national immunisation programmes.
- Current use was projected to avert about 91,000 RSV hospital admissions and 300 RSV deaths in infants each year. This is 3.7% of global admissions and 0.4% of global deaths.
- About 90% of averted admissions and over 70% of averted deaths were projected in high-income countries. Reductions in middle-income countries were under 5% and none were expected in low-income countries.
- The ratio of RSV deaths between the highest and lowest burden quintiles was projected to rise from 18.3 to 20.8, suggesting a possible slight increase in global inequality.
Limitations
This is a projection from a static model that relies on 2019 baseline rates and assumptions about product use. It does not measure real-world outcomes of the programmes, and the estimates carry wide uncertainty ranges.
Abstract
Background: Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection (ALRI) in infants, with low- and middle-income countries (LMICs) bearing a disproportionately high burden. While novel RSV prophylactic products including long-acting monoclonal antibodies and a maternal vaccine are being rolled out for protecting the general infant population in high-income countries, implementation in LMICs is only expected by 2028, potentially exacerbating health inequities. We aimed to assess regional inequality in infant RSV disease burden with and without the implementation of these interventions. Methods: We re-analysed the previous global RSV disease burden dataset in infants by WHO regions and World Bank Income Classification for the year of 2019 as a baseline, using generalised linear mixed-effects models. We developed a static deterministic model that explicitly accounted for the varied risks for RSV admission by birth month and chronological age in month and projected the annual RSV-associated ALRI hospital admissions and RSV-attributable deaths under two scenarios: a no-implementation scenario that assumed the same hospital admission and mortality rates to the 2019 baseline, and a June-2025 product use scenario that was based on country-level implementation status of novel RSV prophylactic products as of June 2025; the two scenarios were then compared to estimate the impact of the current implementation of novel prophylactic products. We further calculated the ratio of RSV-attributable deaths between the highest and lowest burden quintiles (Q5-Q1 ratio) to assess inequality under the two scenarios. Findings: At baseline, the African Region had the highest incidence of RSV-associated ALRI (117.4 per 1000 person-years, 95% uncertainty range, UR: 60.0-229.8) and highest RSV-attributable mortality rate (0.97 per 1000 person-years, 95% UR: 0.76-1.31) while having the lowest RSV-associated ALRI hospital admission rate (12.6 per 1000 person-years; 95% UR: 7.5-21.3); the Eastern Mediterranean Region had the highest hospital admission rate (29.9 per 1000 person-years, 95% UR: 14.2-63.2). The regional variations in incidence, hospital admission, and mortality rates persisted when further stratifying the above estimates by country income level. As of June 2025, nirsevimab and maternal RSVpreF had been licensed in 54 and 64 countries, respectively, with 16 and 12 countries introducing them into their national immunisation programmes. A total of 4,641,000 doses of nirsevimab and 1,955,000 doses of RSVPreF were estimated to be administered annually under the June-2025 product use scenario globally. Administration of both products was projected to jointly avert 91,000 (95% UR: 75,000-118,000) RSV-associated ALRI hospital admissions and 300 (95% UR: 210-470) RSV-attributable deaths in infants annually, corresponding to 3.7% (95% UR: 2.7-4.9) and 0.4% (95% UR: 0.3-0.7) of the global admissions and deaths, respectively. Approximately 90% of averted hospital admissions and over 70% of averted deaths in infants occurred in high-income countries (81,000 [95% UR: 66,000-108,000] and 220 [95% UR: 140-390], respectively), corresponding to reductions of 33.2% (95% UR 31.0-35.9) and 29.1% (95% UR 22.6-35.2); by contrast, the relative reduction of admissions and deaths in middle-income countries was less than 5%, and no reduction was expected in low-income countries. Globally, substantial inequality was observed in the RSV-attributable overall mortality burden under the no-implementation scenario, with the Q5-Q1 ratio of RSV-attributable deaths estimated at 18.3 (95% UR: 11.7-27.5). The June-2025 product use scenario was associated with a possible slight increase in global inequality, with the Q5-Q1 ratio rising to 20.8 (95% UR: 13.0-31.7). Interpretation: The global RSV burden in 2019 varied substantially by region and income level, with the African Region exhibiting the highest incidence and mortality but the lowest hospitalisation rates. The current implementation of novel RSV prophylactic products, characterised by widespread licensing and use in high-income countries and lack of availability in LMICs, particularly the African Region, is projected to yield only modest reductions in the global infant RSV disease burden. Critically, inequitable access to these products may exacerbate existing inequalities in RSV mortality burden. These findings underscore the urgent need for targeted strategies to accelerate the introduction and scale-up of infant RSV immunisation programmes in LMICs. Funding: World Health Organization and National Natural Science Foundation of China (82473692).